A phase III multi-institutional randomized study of immunization with the gp100: 209–217(210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma
2009; Lippincott Williams & Wilkins; Volume: 27; Issue: 15_suppl Linguagem: Inglês
10.1200/jco.2009.27.15_suppl.cra9011
ISSN1527-7755
AutoresDouglas J. Schwartzentruber, D. J. Lawson, Jon Richards, Robert M. Conry, D. M. Miller, J. Triesman, Fawaz Gailani, L Riley, D. Vena, Patrick Hwu,
Tópico(s)Monoclonal and Polyclonal Antibodies Research
ResumoCRA9011 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology. [Table: see text]
Referência(s)